IPO News Archive
Ironwood Pharmaceuticals files for a $173 million IPO

11/23/09


Ironwood Pharmaceuticals, which discovers, develops and intends to commercialize innovative medicines targeting therapeutic needs, filed on Friday with the SEC to raise up to $173 million in an initial public offering. The Boston-based company, which was founded in 1998 and booked $32 million in sales over the last 12 months, plans to list on the NASDAQ under the symbol IRWD. J.P. Morgan, Morgan Stanley and Credit Suisse are the lead underwriters on the deal, for which pricing terms and timing were not disclosed.

View IPO Profile: IRWD         
Related Links: Recently Filed IPOs
Source: www.RenaissanceCapital.com
Latest User Comments
Not a sexy drug... 2/2/2010 10:20:26 AM
Posted by: Opul
But definitely a good market size. Now it just needs to follow through with commercialization, and this could be a good IPO....

Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the IPO Plus Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in the IPO Plus Fund
About Fund Prospectus Invest